Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy.
作者信息
Besson Guillaume J, McMahon Deborah, Maldarelli Frank, Mellors John W
出版信息
Clin Infect Dis. 2012 Feb 1;54(3):451-3. doi: 10.1093/cid/cir721. Epub 2011 Oct 19.
Abstract
摘要
相似文献
1
Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy.在接受有效抗逆转录病毒治疗的患者中，短期使用雷特格韦强化治疗不会增加2长末端重复游离型HIV-1 DNA。
Clin Infect Dis. 2012 Feb 1;54(3):451-3. doi: 10.1093/cid/cir721. Epub 2011 Oct 19.
2
Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.雷特格韦强化治疗期间HIV隐匿性病毒血症和2-LTR形成的空间建模
J Theor Biol. 2014 Mar 21;345:61-9. doi: 10.1016/j.jtbi.2013.12.020. Epub 2013 Dec 28.
3
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.拉替拉韦强化治疗治疗后 2 长末端重复环增加和 D-二聚体减少：一项随机、安慰剂对照试验。
J Infect Dis. 2013 Nov 1;208(9):1436-42. doi: 10.1093/infdis/jit453. Epub 2013 Aug 23.
4
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.拉替拉韦强化治疗对接受抗逆转录病毒治疗的 HIV-1 感染患者血液中病毒复制标志物无影响。
J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):229-35. doi: 10.1097/QAI.0b013e31823fd1f2.
5
Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.拉替拉韦治疗患者和体外感染细胞中 2-长末端重复（2-LTR）环状 HIV-1 DNA 的演变。
J Antimicrob Chemother. 2010 Mar;65(3):434-7. doi: 10.1093/jac/dkp473. Epub 2010 Jan 5.
6
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.整合酶抑制剂拉替拉韦强化治疗可影响 HIV-1 复制和免疫动力学。
Nat Med. 2010 Apr;16(4):460-5. doi: 10.1038/nm.2111. Epub 2010 Mar 14.
7
Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.在血浆病毒载量得到控制的患者中切换至含有拉替拉韦的方案后，HIV-1 总 DNA 和 2 长末端重复环的时间进程。
AIDS. 2010 Sep 24;24(15):2391-5. doi: 10.1097/QAD.0b013e32833d214c.
8
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.在HIV-1病毒血症持续抑制的受试者中使用拉替拉韦加强治疗：一项为期48周的随机研究。
Antivir Ther. 2012;17(2):355-64. doi: 10.3851/IMP1917. Epub 2011 Sep 28.
9
Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.长期治疗男性患者中强化拉替拉韦对血液和肠道黏膜 HIV 前病毒 DNA 的影响：一项随机对照试验。
AIDS. 2012 Jan 14;26(2):167-74. doi: 10.1097/QAD.0b013e32834e8955.
10
Viral persistence in HIV infection: much known, much to learn.HIV感染中的病毒持续存在：已知甚多，仍有许多有待探索。
J Infect Dis. 2013 Nov 1;208(9):1356-8. doi: 10.1093/infdis/jit455. Epub 2013 Aug 23.
引用本文的文献
1
Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs.不同 ART 方案治疗的感染者体内 HIV 标志物的差异：对病毒储存库持续存在的影响。
Viruses. 2020 Apr 27;12(5):489. doi: 10.3390/v12050489.
2
Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen: Results from an Observational Cohort Study.整合酶抑制剂治疗方案转换后免疫激活减少和金葡菌肠毒素 B 诱导的细胞因子产生部分恢复：一项观察性队列研究结果。
Clin Drug Investig. 2019 Dec;39(12):1239-1249. doi: 10.1007/s40261-019-00840-2.
3
Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV.结构导向药物设计鉴定出一种 BRD4 选择性小分子，可抑制 HIV。
J Clin Invest. 2019 Jul 22;129(8):3361-3373. doi: 10.1172/JCI120633.
4
Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane.携带复制型 HIV-1 的扩增细胞克隆持续存在、增加和减少。
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2575-E2584. doi: 10.1073/pnas.1720665115. Epub 2018 Feb 26.
5
Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence.游离型 HIV-1 DNA 及其与 HIV-1 持续存在的其他标志物的关系。
Retrovirology. 2018 Jan 30;15(1):15. doi: 10.1186/s12977-018-0398-1.
6
Prolonged persistence of a novel replication-defective HIV-1 variant in plasma of a patient on suppressive therapy.在接受抑制性治疗的患者血浆中，一种新型复制缺陷型HIV-1变体持续存在。
Virol J. 2016 Sep 21;13(1):157. doi: 10.1186/s12985-016-0617-0.
7
How to Define the Latent Reservoir: Tools of the Trade.如何定义潜伏库：行业工具
Curr HIV/AIDS Rep. 2016 Apr;13(2):77-84. doi: 10.1007/s11904-016-0304-1.
8
A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned.雷特格韦联合抗逆转录病毒疗法用于早期人类免疫缺陷病毒感染的初步研究：挑战与经验教训
Biores Open Access. 2016 Jan 1;5(1):15-21. doi: 10.1089/biores.2015.0038. eCollection 2016.
9
Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.治疗强化后接种 HIV DNA 疫苗和 rAd5 加强疫苗对 HIV 特异性免疫和 HIV 储存库的影响（EraMune 02）：一项多中心随机临床试验。
Lancet HIV. 2015 Mar;2(3):e82-91. doi: 10.1016/S2352-3018(15)00026-0. Epub 2015 Feb 17.
10
The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.Tat抑制剂双脱氢皮质抑素A可防止HIV-1从潜伏状态重新激活。
mBio. 2015 Jul 7;6(4):e00465. doi: 10.1128/mBio.00465-15.
本文引用的文献
1
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.拉替拉韦强化治疗在接受抗逆转录病毒治疗、CD4+T 细胞反应不佳的 HIV 感染患者中的一项随机、对照试验。
J Infect Dis. 2011 Apr 1;203(7):960-8. doi: 10.1093/infdis/jiq138.
2
Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.在接受抑制性抗逆转录病毒治疗的 HIV 阳性成年人的多个肠道部位，含拉替拉韦的强化治疗对 HIV 负荷和 T 细胞激活的影响。
AIDS. 2010 Oct 23;24(16):2451-60. doi: 10.1097/QAD.0b013e32833ef7bb.
3
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.拉替拉韦强化治疗对接受抗逆转录病毒治疗的 HIV 感染患者低水平残留病毒血症的影响：一项随机对照试验。
PLoS Med. 2010 Aug 10;7(8):e1000321. doi: 10.1371/journal.pmed.1000321.
4
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.整合酶抑制剂拉替拉韦强化治疗可影响 HIV-1 复制和免疫动力学。
Nat Med. 2010 Apr;16(4):460-5. doi: 10.1038/nm.2111. Epub 2010 Mar 14.
5
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.强化短程拉替拉韦治疗并未降低联合抗逆转录病毒治疗期间 HIV-1 抑制患者持续低水平病毒血症。
Clin Infect Dis. 2010 Mar 15;50(6):912-9. doi: 10.1086/650749.
6
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.对于接受高效抗逆转录病毒治疗的患者，强化治疗并不能降低残留的HIV-1病毒血症。
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9403-8. doi: 10.1073/pnas.0903107106. Epub 2009 May 22.
7
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.抗逆转录病毒疗法将血浆中的HIV-1 RNA抑制到由治疗前病毒血症预测的稳定水平。
PLoS Pathog. 2007 Apr;3(4):e46. doi: 10.1371/journal.ppat.0030046.
Zotero 插件